Literature DB >> 1983352

Anxiolytic-like action of DuP753, a non-peptide angiotensin II receptor antagonist.

N M Barnes1, B Costall, M E Kelly, D A Murphy, R J Naylor.   

Abstract

The potential of DuP753, an angiotensin II receptor antagonist, to inhibit the suppressed behaviour of mice in a light/dark aversion test was investigated. The aversive response to the light compartment of the apparatus was reduced (increase in latency to move from the light to the dark compartment and decreases in rears, line crossings and percentage of time spent in the dark compartment) following treatment with DuP753 (0.1-1000 micrograms kg-1 p.o., 45 min before the test). These results further implicate the modulation of mental function by angiotensin II.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1983352     DOI: 10.1097/00001756-199009000-00006

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  5 in total

1.  Effects of the selective angiotensin II receptor antagonists losartan and PD123177 in animal models of anxiety and memory.

Authors:  J Shepherd; D J Bill; C T Dourish; S S Grewal; A McLenachan; K J Stanhope
Journal:  Psychopharmacology (Berl)       Date:  1996-08       Impact factor: 4.530

2.  Angiotensin II AT1 receptor blocker candesartan prevents the fast up-regulation of cerebrocortical benzodiazepine-1 receptors induced by acute inflammatory and restraint stress.

Authors:  Enrique Sánchez-Lemus; Masaru Honda; Juan M Saavedra
Journal:  Behav Brain Res       Date:  2012-04-04       Impact factor: 3.332

3.  Strain differences and the role of AT(1) receptor expression in anxiety.

Authors:  Bruno J Golding; Andrew Dj Overall; Paul R Gard
Journal:  Int J Mol Epidemiol Genet       Date:  2010-12-26

4.  Access of peripherally administered DuP 753 to rat brain angiotensin II receptors.

Authors:  K F Song; J L Zhuo; F A Mendelsohn
Journal:  Br J Pharmacol       Date:  1991-12       Impact factor: 8.739

5.  Ability of angiotensin II to modulate striatal dopamine release via the AT1 receptor in vitro and in vivo.

Authors:  D C Brown; L J Steward; J Ge; N M Barnes
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.